- Home
- CELC vs VCV Comparison
CELC vs VCV Comparison
Compare CELC & VCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CELC | VCV |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 530.4M |
| IPO Year | 2017 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CELC | VCV |
|---|---|---|
| Price | $92.43 | $10.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $112.56 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 100.9K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $720.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.42 | $10.03 |
| 52 Week High | $151.02 | $11.38 |
Technical Indicators
Market Signals| Indicator | CELC | VCV |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 51.38 |
| Support Level | $82.48 | $10.51 |
| Resistance Level | $95.59 | $10.75 |
| Average True Range (ATR) | 4.83 | 0.08 |
| MACD | 0.87 | 0.02 |
| Stochastic Oscillator | 79.46 | 65.75 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
About VCV Invesco California Value Municipal Income Trust
Invesco California Value Municipal Income Trust is a closed-end management investment company. Its investment objective is to provide common shareholders with a high level of current income, exempt from federal and California income taxes, consistent with the preservation of capital.